The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

NCT04605861 on ClinicalTrials.gov · last registry update 2023-06-07

Finished 31 December 2022, after enrolling 414 people. Primary outcome, as filed: The percentage of body weight loss. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Shanghai Zhongshan Hospital
Sponsor type: Other
Enrollment: 414
Started: 2020-08-18
Primary completion: 2022-12-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The percentage of body weight loss

Conditions studied

Obese · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.